Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)

被引：1
|
作者：
Ando, M., Sr.
Yonemori, K.
Yunokawa, M.
Nakano, E.
Kouno, T.
Shimizu, C.
Katsumata, N.
Tamura, K.
Arioka, H.
Fujiwara, Y.
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Yokohama Ind Accid Hosp, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.13514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13514
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
    Stathopoulos, GP
    Rigatos, SK
    Dimopoulos, MA
    Giannakakis, T
    Foutzilas, G
    Kouroussis, C
    Janninis, D
    Aravantinos, G
    Androulakis, N
    Agelaki, S
    Stathopoulos, JG
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2003, 14 (03) : 388 - 394
  • [42] A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
    Schoemaker, NE
    Kuppens, IELM
    Moiseyenko, V
    Glimelius, B
    Kjaer, M
    Starkhammer, H
    Richel, DJ
    Smaaland, R
    Bertelsen, K
    Poulsen, JP
    Voznyi, E
    Norum, J
    Fennelly, D
    Tveit, KM
    Garin, A
    Gruia, G
    Mourier, A
    Sibaud, D
    Lefebvre, P
    Beijnen, JH
    Schellens, JHM
    Huinink, WWT
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1434 - 1441
  • [43] Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer
    Sugiyama, T
    Yakushiji, M
    Nishida, T
    Ushijima, K
    Okura, N
    Kigawa, J
    Terakawa, N
    CANCER LETTERS, 1998, 128 (02) : 211 - 218
  • [44] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Shiozawa, Manabu
    Sugano, Nobuhiro
    Tsuchida, Kazuhito
    Morinaga, Soichiro
    Akaike, Makoto
    Sugimasa, Yukio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (03) : 365 - 370
  • [45] Phase I study of irinotecan (CPT-11) combined with S-1 in patients with advanced gastric cancer(AGC)
    Komatsu, Y
    Takei, M
    Kato, T
    Miyagishima, T
    Kunieda, Y
    Tateyama, M
    Wakahama, O
    Takeda, H
    Kato, M
    Sugiyama, T
    Asaka, M
    Sakata, Y
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 253 - 254
  • [46] A phase I/II study of 24-hour infusional irinotecan (CPT-11) therapy in metastaic colorectal cancer.
    Tsui, A
    Kobayashi, K
    Shima, Y
    Hamada, M
    Nishioka, Y
    Morita, S
    Horimi, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 289S - 289S
  • [47] Phase II study of irinotecan (CPT-11) in patients with 5-Fluorouracil-refractory metastatic colorectal carcinoma - An Asian experience
    Ang, PCS
    Koo, WH
    Au, E
    Ang, PT
    Khoo, KS
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
  • [48] Phase I/II trial of gemcitabine (Gem) plus irinotecan (CPT-11) for metastatic pancreatic cancer (MPC)
    Yamai, Takuo
    Ioka, Tatsuya
    Sueyoshi, Hironari
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [49] Irinotecan (CPT-11) in pretreated metastatic colorectal cancer (CRC)
    Lara, MA
    Feliu, J
    Salinas, P
    Fernandez, Y
    Garcia-Giron, C
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 46
  • [50] A phase I study of amrubicin (AMR) and irinotecan (CPT-11) in relapsed small cell lung cancer
    Mio, T.
    Kawahara, M.
    Fukushima, M.
    Yanagihara, K.
    Daimon, T.
    Furuse, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345